Business combinations - Acquisition-related costs (Details) - TCR2 Therapeutics $ in Thousands |
6 Months Ended |
|---|---|
|
Jun. 30, 2023
USD ($)
| |
| Merger with TCR2 Therapeutics Inc. | |
| Legal, professional and accounting fees | $ 4,993 |
| Bankers' fees | 2,172 |
| Total acquisition-related costs | 7,165 |
| Issuance costs incurred relating to the issuance of shares to TCR2 stockholders | $ 0 |
| X | ||||||||||
- Definition Amount of bankers' fees incurred to effect a business combination which costs have been expensed during the period. No definition available.
|
| X | ||||||||||
- Definition Amount of legal, professional and accounting fees incurred to effect a business combination which costs have been expensed during the period. No definition available.
|
| X | ||||||||||
- Definition Amount of issuance costs incurred relating to the issuance of shares to acquiree's stockholders, to effect a business combination which costs have been expensed during the period. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|